Aoran Biotechnology

Aoran Biotechnology (Shanghai) Co., Ltd. was established in 2015, focusing on point-of-care molecular diagnostic technology. The founders have successful entrepreneurial experiences in Silicon Valley, USA, and mainland China, and its core technical team has years of R&D experience in the molecular diagnostics field. The company headquarters is located in Shanghai International Medical Park, with an R&D and production area exceeding 4,000 square meters. It has a 750-square-meter reagent R&D center on Guangzhou International Bio-Island and a 2,300-square-meter automated production line for instruments and smart cartridges in Shenzhen, with business covering all regions nationwide and overseas. As of February 2022, the company has filed 95 domestic and international intellectual property applications, obtained 73 authorizations, including 10 invention patents, 30 utility model patents, and 24 design patents; filed 5 international patents; obtained 9 software copyrights; and filed 22 trademark applications, with 13 authorizations obtained. Aoran Biotechnology has obtained 4 Class III medical device registration certificates; its independently developed fully automatic, fully sealed fluorescence PCR integrated system (Galaxy Nano/ Galaxy Lite/ Galaxy Pro) and supporting multiple nucleic acid detection reagent products have received EU CE certification. The innovative molecular diagnostic technology and products have gained favor from professional institutions. In 2018, Aoran Biotechnology was selected for the national "13th Five-Year Plan" major special project for infectious diseases, the "Multi-center Evaluation of Combined Diagnostic Technology for Tuberculosis," where its IGS TB/RIF Lite product participated in the evaluation and passed the assessment. In 2020, Aoran Biotechnology was listed by the Shanghai Municipal Commission of Economy and Informatization as an emergency requisition unit for epidemic prevention and control.